title: Tissue factor and tissue factor pathway inhibitor in women with a past history of preeclampsia: implication for a hypercoagulable state postpregnancy.
abstract: Preeclampsia (P-EC) is a multisystem disorder of pregnancy whose cause and pathogenesis remain poorly understood. However, abnormal haemostasis and endothelial dysfunction are thought to be implicated. Women with a past medical history of P-EC have a baseline hypercoagulable state postpregnancy. The aim of this study is to examine the relationship between tissue factor (TF) and TF pathway inhibitor (TFPI) in women who have had P-EC within the last 3 years (more than 6 months postpartum) and their normal counterparts. Blood specimens were collected from women known to have had P-EC within the last 3 years (n = 26) and aged-matched healthy women without past history of P-EC in previous pregnancy (n = 26). Plasma TF and TFPI levels were measured using ELISAs. Women who have had P-EC showed increased TF levels compared with their normal counterparts, whereas TFPI levels were reduced. Neither parameter differed significantly when the groups were tested against each other. Interestingly, the TF/TFPI ratio was significantly increased (P = 0.024) when the two groups were compared. In summary, there was a trend towards increased TF and reduced TFPI levels in the P-EC group. Such a tendency was not statistically significant. However, the TF/TFPI ratio was significantly increased when the groups were compared. Our findings suggest an imbalance between TF/TFPI levels in women with past history of P-EC postpregnancy. This may contribute to the development of maternal hypercoagulable states and may predispose women with a history of P-EC to cardiovascular risks later in life.
authors.affiliation: aFaculty of Health Sciences bFaculty of Medicine, University of Southampton cThe Wessex Cardiothoracic Centre dDepartment of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK eFaculty of Pharmacy, Federal University of Minas Gerais, Minas Gerais, Brazil fFaculty of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
authors.forename: Bashir A
authors.initials: BA
authors.lastname: Lwaleed
authors.forename: Mohamed O
authors.initials: MO
authors.lastname: Breish
authors.forename: Brian R
authors.initials: BR
authors.lastname: Birch
authors.forename: Azeem P
authors.initials: AP
authors.lastname: Chowdhary
authors.forename: Rasheed A
authors.initials: RA
authors.lastname: Saad
authors.forename: Oliver
authors.initials: O
authors.lastname: Perigo
authors.forename: Rashid S
authors.initials: RS
authors.lastname: Kazmi
authors.forename: Luci M
authors.initials: LM
authors.lastname: Dusse
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Cooper
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D019851:Thrombophilia / Q000097:blood*; D013925:Thromboplastin / Q000378:metabolism*; D055815:Young Adult
chemical_list: D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin